A prospective study to assess the impact of pharmacist-led patient-centered interventions in schizophrenia
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 108
- Locations
- 1
- Primary Endpoint
- Impact of pharmaceutical care in improvement or prevention cardiometabolic diseases in schizophrenia by controlling weight gain & obesity will be studied
Study Overview
Brief Summary
Schizophrenia is a serious mental disorder of unknown origin. This complex disorder requires lifelong therapy with antipsychotics. The long-term therapy of antipsychotics and an unhealthy lifestyle enhance the risk of cardiometabolic diseases like hypertension, diabetes and dyslipidemia, weight gain and obesity, resulting in poor quality of life. Weight gain and obesity are two critical issues in schizophrenia. Both factors can unfavourably affect the schizophrenic patient by increasing the risk of cardiometabolic diseases. An estimated 60% of schizophrenic patients stop taking medications after 2-3 months and 80% in 2 years. The non-adherence rate of schizophrenia is estimated at 60-70%. This reduces the quality of life and proportionally elevates the economic burden on schizophrenia patients. Hence, the study’s primary purpose is to assess the impact of pharmaceutical care on schizophrenia. The proposed study aims to test the hypothesis of whether pharmacist interventions yield better outcomes on schizophrenia patients.
Study Design
- Study Type
- Interventional
- Allocation
- Coin toss, Lottery, toss of dice, shuffling cards etc
- Masking
- Open Label
Eligibility Criteria
- Ages
- 18.00 Year(s) to 65.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Patient or caretaker Patient or caretaker willing to provide informed consent Patients aged ≥ 18 and ≤ 65 years old Patients diagnosed with schizophrenia and schizophrenia spectrum disorders who were on the treatment of antipsychotic drugs with or without co-morbidities of hypertension, diabetes, hypercholesterolemia and weight gain Both genders.
Exclusion Criteria
- •Patient or caretaker unwilling to provide consent Patients with other severe chronic medical conditions, including cancer, end-stage renal disease, heart failure and HIV Patients with a diagnosis of Cushing syndrome, hypothyroidism, eating disorder Patients who are engaged in the weight management programs within the past 3 months Patients who are taking other forms of medicines to control weight including Ayurvedha, Homeopathy Patients with co-existing physical illnesses that reduce their ability to participate in the study.
Outcomes
Primary Outcomes
Impact of pharmaceutical care in improvement or prevention cardiometabolic diseases in schizophrenia by controlling weight gain & obesity will be studied
Time Frame: 0 4 8 12 months
Secondary Outcomes
- Secondary outcomes: Measurement of medication adherence, quality of life and comparing the economic burden of schizophrenic patients by cost of illness study(0 4 8 12 months)